Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple-Drug cocktail aims to boost remission in follicular lymphoma

NCT ID NCT06471738

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of three drugs—zanubrutinib, rituximab, and venetoclax—in people with previously untreated follicular lymphoma. The goal is to see if this mix can improve the rate of complete remission (disappearance of cancer). Participants receive all three drugs, and the study tracks how well the cancer responds and how long it stays away.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of zanubrutinib, rituximab, and venetoclax
What this could lead to
If successful, this drug combination could offer a more effective first treatment for follicular lymphoma, potentially leading to higher remission rates.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The combination also carries risks of side effects like infections or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE II FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANN ARBOR STAGE II FOLLICULAR LYMPHOMA ANN ARBOR STAGE III FOLLICULAR LYMPHOMA ANN ARBOR STAGE IV FOLLICULAR LYMPHOMA GRADE 1 FOLLICULAR LYMPHOMA GRADE 2 FOLLICULAR LYMPHOMA GRADE 3A FOLLICULAR LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital

    RECRUITING

    Beijing, 100853, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.